Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $17
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $15 to $17.
Citizens analyst Silvan Turkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and raises the price target from $15 to $17.